Bluejay Diagnostics Inc (BJDX) - Total Liabilities
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has total liabilities worth $1.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BJDX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Bluejay Diagnostics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data.
Bluejay Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Bluejay Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Robert Walters
LSE:RWA
|
UK | GBX193.30 Million |
|
Zephyr Energy PLC
LSE:ZPHR
|
UK | GBX34.75 Million |
|
NeutriSci International Inc
V:NU
|
Canada | CA$1.04 Million |
|
Braemar Plc
LSE:BMS
|
UK | GBX69.89 Million |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
UK | GBX11.69 Million |
|
Kovo Healthtech Corp
V:KOVO
|
Canada | CA$26.79 Million |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
France | €1.05 Million |
|
EnSilica PLC
LSE:ENSI
|
UK | GBX21.71 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Bluejay Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bluejay Diagnostics Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bluejay Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual total liabilities of Bluejay Diagnostics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.14 Million | +23.28% |
| 2024-12-31 | $927.92K | -52.99% |
| 2023-12-31 | $1.97 Million | -0.32% |
| 2022-12-31 | $1.98 Million | +210.75% |
| 2021-12-31 | $637.16K | -88.87% |
| 2020-12-31 | $5.72 Million | +48.70% |
| 2019-12-31 | $3.85 Million | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more